SCHEMBL20120231

SCHEMBL20120231

FC(F)(CCCOC1CC(OCc2ccccc2)C1)COC1CCCCO1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ KDM4C Q9H3R0 1/20 0.36
▸ TACR1 P25103 1/20 0.35
▸ SLC18A3 Q16572 1/20 0.33
▸ BCHE P06276 3/20 0.32
▸ EP300 Q09472 1/20 0.32
▸ CREBBP Q92793 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ ICAM1 P05362 1/20 0.32
▸ SELE P16581 1/20 0.32
▸ SIGMAR1 Q99720 1/20 0.31
▸ DPP4 P27487 1/20 0.31
▸ OPRM1 P35372 1/20 0.31
▸ OPRL1 P41146 1/20 0.31
▸ GBA1 P04062 1/20 0.31
▸ SI P14410 1/20 0.31
▸ UGCG Q16739 1/20 0.31
▸ GBA2 Q9HCG7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20133221 1.00 MEN1 (0.39) MEN1KMT2AKDM4CTACR1SLC18A3
SCHEMBL27098740 0.89 TACR1 (0.39) MEN1KMT2AKDM4CTACR1SLC18A3
SCHEMBL29773833 0.89 TACR1 (0.39) MEN1KMT2AKDM4CTACR1SLC18A3
SCHEMBL20128955 0.86 MEN1 (0.50) MEN1KMT2AKDM4CTACR1SLC18A3
SCHEMBL21751819 0.86 MEN1 (0.47) MEN1KMT2AKDM4CTACR1SLC18A3
SCHEMBL20133087 0.86 MEN1 (0.50) MEN1KMT2AKDM4CTACR1SLC18A3
SCHEMBL20128933 0.86 MEN1 (0.50) MEN1KMT2AKDM4CTACR1SLC18A3
SCHEMBL21771133 0.86 MEN1 (0.47) MEN1KMT2AKDM4CTACR1SLC18A3
SCHEMBL20133212 0.84 MEN1 (0.48) MEN1KMT2AKDM4CTACR1BCHE
SCHEMBL20120795 0.84 MEN1 (0.46) MEN1KMT2AKDM4CTACR1SLC18A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559486-B2 Tau-protein targeting compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-24 — — US disclosed
CN-119954801-A TAU protein targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2025-05-09 — — CN disclosed
CN-114867727-B TAU protein targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2025-02-21 — — CN disclosed
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-07-04 — — US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 — — US disclosed
US-20230086457-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-23 — — US disclosed
US-20220315575-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-10-06 — — US disclosed
US-11458123-B2 Tau-protein targeting PROTACs and associated methods of use ARVINAS OPERATIONS, INC. (US) 2022-10-04 — — US disclosed
CN-114867727-A TAU protein targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2022-08-05 — — CN disclosed
EP-3999182-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2022-05-25 — — EP disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 — — WO disclosed
EP-3535265-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2019-09-11 — — EP disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 — — WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315575-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT MEN1 1910/4885KMT2A 1588/4885KDM4C 2142/4885
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN MEN1 1944/4885KMT2A 1250/4885KDM4C 2111/4885
US-20230086457-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 MEN1 1972/4885KMT2A 1074/4885KDM4C 1589/4885
US-11458123-B2 Tau-protein targeting PROTACs and associated methods of use CRBN, VHL, UBQLN2 MEN1 1972/4885KMT2A 1074/4885KDM4C 1589/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 MEN1 1972/4885KMT2A 1074/4885KDM4C 1589/4885
US-20240217962-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE VHL, CRBN, MAPT MEN1 1910/4885KMT2A 1588/4885KDM4C 2142/4885
US-12559486-B2 Tau-protein targeting compounds and associated methods of use UBQLN2, UBQLN1, CRBN MEN1 1955/4885KMT2A 767/4885KDM4C 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback